Showing results (351-360 of 449) with videos related to

Sort By:
Pageof 45
British Journal of Haematology|December 1, 1996
A pilot study of 220 mg/m2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicityP Moreau, M F Kergueris, N Milpied, et al.
Leukemia|January 15, 2010
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasoneH Avet-Loiseau, J Soulier, J-P Fermand, et al.
Journal of Medicinal Chemistry|October 28, 1997
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl groupF Anizon, L Belin, P Moreau, et al.
Genes and Immunity|December 20, 2013
Worldwide genetic variation at the 3' untranslated region of the HLA-G gene: balancing selection influencing genetic diversityA Sabbagh, P Luisi, E C Castelli, et al.
The Journal of Biological Chemistry|April 15, 1988
Probing peptide backbone function in bombesin. A reduced peptide bond analogue with potent and specific receptor antagonist activityD H Coy, P Heinz-Erian, N Y Jiang, et al.
Annals of Hematology|March 17, 2010
Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myelomaA Palumbo, F Davies, M Kropff, et al.
Tissue Antigens|March 28, 2012
Identification of two new HLA-G alleles, G*01:01:03:03 and G*01:01:21, in Brazilian individualsE C Castelli, R S de Albuquerque, L C Veiga-Castelli, et al.
Blood Cancer Journal|February 25, 2014
Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myelomaD S Siegel, P Richardson, M Dimopoulos, et al.
The Journal of Biological Chemistry|September 15, 1990
des-Met carboxyl-terminally modified analogues of bombesin function as potent bombesin receptor antagonists, partial agonists, or agonistsL H Wang, D H Coy, J E Taylor, et al.
Genes and Immunity|November 14, 2014
Balancing immunity and tolerance: genetic footprint of natural selection in the transcriptional regulatory region of HLA-GL Gineau, P Luisi, E C Castelli, et al.
Pageof 45